Enhancing FDA Drug-Safety Surveillance — Beyond Releasing Daily Adverse-Event Data
J
Joshua D. Wallach
(Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta)
J
Joseph S. Ross
(Section of General Medicine, Department of Medicine, Yale School of Medicine, New Haven, CT)
R
Reshma Ramachandran
(Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale University School of Medicine, New Haven, CT)
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 393, Issue 23
Published
December 11, 2025
Pages
2284-2286
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (3)
J
Joshua D. Wallach
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta
J
Joseph S. Ross
Section of General Medicine, Department of Medicine, Yale School of Medicine, New Haven, CT
R
Reshma Ramachandran
Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale University School of Medicine, New Haven, CT
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582